ABBV
AbbVie Inc
AbbVie Inc historical holders
total: 14
Tweedy, Browne Co All Funds (US) AbbVie Inc transactions over time
- Total transactions:
- 6
- New positions:
- 1
- Sold out:
- 1
- Added:
- 2
- Reduced:
- 2
- Held since:
- 2020 Q2
- Held for:
- 5 quarters
- Latest activity:
- 2021 Q3
Tweedy, Browne Co All Funds (US) has been an institutional investor in AbbVie Inc (ABBV) since 2020 Q2. According to 2026 Q1 report, Tweedy, Browne Co All Funds (US) doesn't hold any shares. The fund/company first acquired ABBV in 2020 Q2, initially purchasing 206,000 shares. Since the initial investment, Tweedy, Browne Co All Funds (US) has made 5 more transactions in this position.
When did Tweedy, Browne Co All Funds (US) exit their ABBV position?
Tweedy, Browne Co All Funds (US) no longer holds AbbVie Inc (ABBV). They sold off their entire position in 2021 Q3, closing out an investment that began in 2020 Q2.
When did Tweedy, Browne Co All Funds (US) first invest in ABBV?
Tweedy, Browne Co All Funds (US) first invested in AbbVie Inc (ABBV) in 2020 Q2 at the reported quarter-end price of $98.18 per share, acquiring 206,000 shares in their initial purchase.
What is Tweedy, Browne Co All Funds (US)'s average cost basis for ABBV?
Based on historical transaction data, Tweedy, Browne Co All Funds (US)'s estimated cost basis for AbbVie Inc (ABBV) is approximately $97.64 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $97.64
- Weighted AVG sell price:
- $112.63
ABBV transactions history by Tweedy, Browne Co All Funds (US)
6 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2021 Q3
|
0.00%
|
0
|
$112.64
|
|
-100% (-390,370)
|
-1.24%
|
|
2021 Q2
|
1.24%
|
390,370
|
$112.64
|
$43,971,000
|
-0.31% (-1,225)
|
-0%
|
|
2021 Q1
|
1.23%
|
391,595
|
$108.22
|
$42,378,000
|
-0.16% (-640)
|
-0%
|
|
2020 Q4
|
1.31%
|
$107.15
|
+29.74% (+89,915)
|
|||
|
2020 Q3
|
1.03%
|
$87.59
|
+46.76% (+96,320)
|
|||
|
2020 Q2
|
0.81%
|
$98.18
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.